The PARP inhibitor olaparib was recently evaluated in a phase I clinical trial and showed antitumour activity in BRCA1 or BRCA2 mutation carriers with ovarian, breast or prostate cancer (Fong et al, 2009). The gene discussed is BRCA1; the disease is prostate cancer.